Century Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
165
- Stock Symbol
-
IPSC
- Investments
-
2
- Share Price
-
$0.56
- (As of Friday Closing)
Century Therapeutics General Information
Description
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Contact Information
Website
www.centurytx.comCorporate Office
- 25 North 38th Street
- 11th Floor
- Philadelphia, PA 19104
- United States
Corporate Office
- 25 North 38th Street
- 11th Floor
- Philadelphia, PA 19104
- United States
Century Therapeutics Stock Performance
As of 21-Mar-2025, Century Therapeutics’s stock price is $0.56. Its current market cap is $47.8M with 85M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.56 | $0.55 | $0.52 - $4.78 | $47.8M | 85M | 498K | -$1.61 |
Century Therapeutics Financials Summary
As of 31-Dec-2024, Century Therapeutics has a trailing 12-month revenue of $6.59M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (57,637) | (57,637) | 76,722 | (6,050) |
| Revenue | 6,589 | 6,589 | 2,235 | 5,199 |
| EBITDA | (124,479) | (124,479) | (133,885) | (125,621) |
| Net Income | (126,566) | (126,566) | (136,673) | (130,932) |
| Total Assets | 353,216 | 353,216 | 360,691 | 486,544 |
| Total Debt | 53,830 | 53,830 | 48,171 | 49,414 |
Century Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Century Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Century Therapeutics Comparisons
Industry
Financing
Details
Century Therapeutics Competitors (86)
One of Century Therapeutics’s 86 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Lyell Immunopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Century Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Century Therapeutics Patents
Century Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023284442-A1 | Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof | Pending | 08-Jun-2022 | ||
| US-20250090582-A1 | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof | Pending | 08-Jun-2022 | ||
| EP-4519319-A1 | Cells engineered with an hla-e and hla-g transgene | Pending | 04-May-2022 | ||
| US-20230381317-A1 | Methods for controlled activation and/or expansion of genetically engineered cells using polyethylene glycol (peg) receptors | Pending | 21-Apr-2022 | ||
| AU-2022423987-A1 | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof | Pending | 29-Dec-2021 | A61K40/4212 |
Century Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Century Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Century Therapeutics Acquisitions (2)
Century Therapeutics’s most recent deal was a Merger/Acquisition with Clade Therapeutics for . The deal was made on 11-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Clade Therapeutics | 11-Apr-2024 | Merger/Acquisition | Biotechnology | ||
| Empirica Therapeutics | 23-Jun-2020 | Merger/Acquisition | Drug Discovery |
Century Therapeutics ESG
Risk Overview
Risk Rating
Updated May, 24, 2023
27.47 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Century Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Empirica Therapeutics | Hamilton, Canada | 2018 |
Century Therapeutics FAQs
-
When was Century Therapeutics founded?
Century Therapeutics was founded in 2018.
-
Where is Century Therapeutics headquartered?
Century Therapeutics is headquartered in Philadelphia, PA.
-
What is the size of Century Therapeutics?
Century Therapeutics has 165 total employees.
-
What industry is Century Therapeutics in?
Century Therapeutics’s primary industry is Drug Discovery.
-
Is Century Therapeutics a private or public company?
Century Therapeutics is a Public company.
-
What is Century Therapeutics’s stock symbol?
The ticker symbol for Century Therapeutics is IPSC.
-
What is the current stock price of Century Therapeutics?
As of 21-Mar-2025 the stock price of Century Therapeutics is $0.56.
-
What is the current market cap of Century Therapeutics?
The current market capitalization of Century Therapeutics is $47.8M.
-
What is Century Therapeutics’s current revenue?
The trailing twelve month revenue for Century Therapeutics is $6.59M.
-
Who are Century Therapeutics’s competitors?
Fate Therapeutics, Lyell Immunopharma, Caribou Biosciences, Allogene Therapeutics, and CytomX Therapeutics are some of the 86 competitors of Century Therapeutics.
-
What is Century Therapeutics’s annual earnings per share (EPS)?
Century Therapeutics’s EPS for 12 months was -$1.61.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
